Breast cancer funding sources
Pro Research Analysisby 
Searched over 200M research papers
Global Patterns in Breast Cancer Research Funding
Breast cancer research receives significant global investment, with $2.6 billion allocated between 2016 and 2020, representing 11.2% of all public and philanthropic cancer research funding during this period. The United States is the largest contributor, accounting for nearly 67% of global breast cancer research investment, followed by China and the UK. However, funding for breast cancer research has declined year-on-year, dropping from $773.4 million in 2016 to $243.8 million in 2020. Most of this funding is directed toward pre-clinical research, with smaller proportions allocated to clinical trials and public health research. Surgery and radiotherapy, despite their importance in treatment, receive only a small fraction of the total investment. There is also minimal funding for breast cancer as a global health issue, especially in low- and middle-income countries, which bear an increasing share of the disease burden 28.
Funding Sources: Government, Industry, and Philanthropy
Government funding tends to focus on molecular and population-level research, while non-governmental sources, including industry and private organizations, are more likely to support studies centered on individual patients and specific treatments. This reflects the differing priorities of public institutions and the private sector . Industry funding is prevalent in clinical trials that inform treatment guidelines, with its share increasing over time. Industry-sponsored studies are more likely to report positive outcomes favoring the experimental treatment, a trend not observed in studies funded by cooperative groups or government sources .
Philanthropic organizations, such as the Breast Cancer Research Foundation (BCRF), play a unique role by fostering collaborations between academia and industry. Programs like the BCRF Drug Research Collaborative aim to support investigator-initiated trials and translational research, addressing gaps left by traditional industry-sponsored drug development .
Allocation of Funding by Research Area
The majority of breast cancer research funding is invested in cancer biology and drug treatment, with less emphasis on diagnosis, screening, monitoring, surgery, and radiotherapy. For example, cancer biology research received 37.5% of the investment, while surgery and radiotherapy accounted for only 2.5% and 1.4%, respectively. Research into metastatic breast cancer (MBC) has seen increased investment, with a higher proportion of breast cancer research funds directed toward metastasis compared to other cancer types. However, the overall funding for metastatic research remains insufficient relative to its impact on mortality 2478.
Influence of Funding Source on Research Outcomes and Representation
Pharmaceutical industry funding is associated with a higher likelihood of favorable conclusions in cost-effectiveness studies and clinical trials. These studies are more likely to focus on high-income countries and often compare drugs within the same class. There is a notable lack of research representing the perspectives and needs of low- and middle-income countries, as well as underrepresented populations 36.
Disparities and Gaps in Funding
While breast cancer receives substantial funding compared to other cancers, disparities exist. Funding correlates more strongly with disease incidence than with mortality, leading to underfunding of cancers with high mortality rates and those disproportionately affecting Black patients. This underfunding is linked to fewer clinical trials and potentially slower progress in these areas . Additionally, there is a need for more equitable distribution of research funding to address the global burden of breast cancer and to support research relevant to diverse populations 289.
Conclusion
Breast cancer research funding is substantial but unevenly distributed across research areas, countries, and populations. Government, industry, and philanthropic sources each shape the research agenda in distinct ways, with industry funding often linked to more favorable study outcomes. Despite progress, significant gaps remain, particularly in funding for metastatic disease, surgery, radiotherapy, prevention, and research relevant to low- and middle-income countries. Addressing these disparities is essential for aligning research investment with patient needs and the global burden of breast cancer.
Sources and full results
Most relevant research papers on this topic